Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 27th International Diabetes and Healthcare Conference Abu Dhabi, UAE.

Day 1 :

Keynote Forum

Suzan Darwish,

Alexandria University, Egypt

Keynote: Updates of the pharmacotherapy of diabetes mellitus

Time : 09:30-10:30

Diabetic 2019 International Conference Keynote Speaker Suzan Darwish, photo
Biography:

Suzan Darwish has completed her BPharm, MSc from faculty of Pharmacy, Alexandria University, Egypt; PhD in Pharmacology from
Strathclyde University, UK. Worked as Professor of Pharmacology in Faculty of Medicine, University of Alexandria, Egypt, from 1988 until 2003 then acted as head of the same department until 2005. She is now Emeritus Professor in Pharmacology, Faculty of Medicine, Alexandria University, since 2005.Published 35 papers in reputed journals and supervised 14 MSc/ PhD thesis Elected as president of the Egyptian Association of the Advancement of Basic Medical Sciences (EAMBS) from 2003 up till now.

Abstract:

Despite the known benefits of a healthy lifestyle, many individuals find it hard to maintain such a lifestyle in the modern world, which facilitates sedentary behavior and overeating. Consequently, the prevalence of type 2 diabetes mellitus is predicted to increase dramatically over the coming years. To counteract the resulting impact on morbidity and mortality of the disease, a tremendous number of new treatments available for diabetes was poured into the market Research lines in diabetes can be grouped into three main categories: technological, biological, and pharmacological with the latter category, pharmacological research, appears the most effective for significantly reducing the burden of type 2 diabetes mellitus. However, the success of antidiabetic medication has also been limited by their mechanism of action and side effects. A big number of promising new drugs were developed to achieve newer antidiabetic medication including oral insulin, gene therapy, the incretins, dipeptidyl peptidase-4 inhibitors, peroxisome proliferator-activated receptor inhibitors,and sodium–glucose cotransporter inhibitors to treat Type 2 diabetes mellitus. However, the up to date, current standard of care for diabetes management is not enough for long run benefits to diabetic patients. The aim of my talk is to provide a brief overview of current antidiabetic drugs & updates on diabetes management for clinical usage.

Break: Networking and Refreshments Break with Group Photo @10:30-10:45

Keynote Forum

Mohamad Miqdady

Sheikh Khalifa Medical City, UAE

Keynote: Chubby child ≠ Cute child!

Time : 10:45-11:45

Diabetic 2019 International Conference Keynote Speaker Mohamad Miqdady photo
Biography:

Mohamad Miqdady is American Board certified in Pediatric Gastroenterology, Hepatology and Nutrition. He is the Division Chief, Ped. GI, Hepatology & Nutrition Division at Sheikh Khalifa Medical City in UAE. Program Director, Pediatric Gastroenterology Fellowship Training program, SKMC, Abu Dhabi, UAE. Also an Adjunct Staff at Cleveland Clinic, Ohio USA. Expert member of the FISPGHAN Council (Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition); Malnutrition/Obesity Expert team. Dr. Miqdady completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children’s Hospital in Houston, TX, USA. He held the position of Assistant Professor at Jordan University of Science and Technology in Jordan for six years prior joining. SKMC Main research interests include nutritional disorders, feeding difficulties, picky eating, obesity, procedural sedation, allergic GI disorders and celiac disease.He has 20 publications in peer reviewed journals. On the Editorial Board of few journals including Gastroenterology & Hepatology.
 

Abstract:

Obesity epidemic is a very serious concern for the medical professionals as well as the community. It is estimated that 30-35 % of children in US are overweight or obese, and probably higher percentages applyin our community. Local data will be presented. Overweight is defined as a BMI of & gt; 85%, and obesity if BMI
> 95%. BMI correlates very well with comorbidities. Obesity occurs when there is imbalance between energy intake and energy output. There is a universal trend towards decreasing physical activity and increasing dietary intake among adults and children. Unlike the animal model, most obese humans are leptin resistant rather than deficient. Childhood obesity is clearly associated with adulthood obesity, with the strongest association if obesity occurs at later childhood. Obese children are usually taller with advanced bone age and enter puberty earlier. Comorbidities are many and involve almost all body systems: CVS: Hypertension, coronary artery disease, pulmonary hypertension corpulmonale. Cardiomyopathy and atherosclerosis.Pulmonary: Obstructive sleep apnea, and Pickwickian syndrome. Gastrointestinal: Gallbladder diseases, nonalcoholic steatohepatitis and reflux. CNS: Stroke and increased intracranial pressure. Orthopedic: Osteoarthritis, slipped capital femoral epiphyses, low back pain, and Legg-Calve-Perthes disease Psychological: Social stigmatization, Depression and lack of self esteem Endocrine: Early puberty, hyperandrogenism, anovulation, infertility, polycystic Ovaries and hypo-gonadotrophic hypogonadism Malignancy: Increased risk of malignancy: endometrial cancer, prostate cancer, gall bladder cancer, Breast cancer, colon cancer Metabolic: Insulin resistance, type II DM, Dyslipidemia (cholesterol, TG, LDL, HDL) Although genetic and hormonal causes are rare causes of obesity; they should always be kept in mind. Managing obese individuals is challenging and with limited success. Management should include exercise, diet, and behavioral modification. Exercise should be 30-60 minutes 5-7 days a week. Normal or, low calorie diets with the appropriate use of the food pyramid are to be used in most individuals. Medications and surgery can be included in certain indications in conjunction with diet and exercise.